Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
ex-vivo expanded allogeneic γδT cells / Beijing GD
NCT04518774: Allogeneic "Gammadelta T Cells (γδ T Cells)" Cell Immunotherapy in Phase 1 Hepatocellular Carcinoma Clinical Trial	Recruiting	1	8	RoW	Ex-vivo expanded allogeneic γδT cells	Beijing 302 Hospital, Chinese Academy of Medical Sciences, Beijing GD Initiative Cell Therapy Technology Co., Ltd.	Hepatocellular Carcinoma	06/21	08/21
NCT04696705: Allogeneic γδ T Cells Immunotherapy in r/r Non-Hodgkin's Lymphoma (NHL) or Peripheral T Cell Lymphomas (PTCL) Patients	Recruiting	1	10	RoW	Ex-vivo expanded allogeneic γδT cells	Institute of Hematology & Blood Diseases Hospital, Beijing GD Initiative Cell Therapy Technology Co., Ltd., Chinese Academy of Medical Sciences	Non-Hodgkin's Lymphoma (NHL), Peripheral T Cell Lymphoma (PTCL)	12/21	12/23
NCT06212388: Allogeneic Gammadelta T Cells Combined With Interferon-α1b or PD-1 Monoclonal Antibody in Stage III-IV Amenable to Surgical Resection Melanoma	Not yet recruiting	1	10	NA	Ex-vivo expanded allogeneic γδ T cells, Recombinant human interferon α1b, Pembrolizumab	Xijing Hospital, Beijing GD Initiative Cell Therapy Technology Co., Ltd.	Melanoma	10/27	10/28